The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 12; no. 18; pp. 2603 - 2606
Main Authors BLACKIE, Josie A, BLOOMER, Jackie C, MACPHEE, Colin H, MILLINER, Kevin J, MOORES, Kitty E, PINTO, Ivan L, SMITH, Stephen A, STANSFIELD, Ian G, STANWAY, Steven J, TAYLOR, Maxine A, THEOBALD, Colin J, WHITTAKER, Caroline M, BROWN, Murray J. B, CHENG, Hung-Yuan, ELLIOTT, Richard L, HAMMOND, Beverley, HICKEY, Deirdre M. B, IFE, Robert J, LEACH, Colin A, LEWIS, V. Ann
Format Journal Article
LanguageEnglish
Published Oxford Elsevier 16.09.2002
Subjects
Biological and medical sciences
General and cellular metabolism. Vitamins
Medical sciences
Pharmacology. Drug treatments
Nitrogen heterocycle
Rabbit
Cardiovascular disease
Lipids
Esterases
Vascular disease
Lipoprotein LDL
Prevention
Structure activity relation
Six membered ring
Atherosclerosis
Pyrazole derivatives
Hyperlipemia
Dyslipemia
Chemical synthesis
Human
Enzyme
Benzene derivatives
Oral administration
Enzyme inhibitor
Metabolic diseases
Artificial membrane
Bioavailability
Permeability
Lagomorpha
In vitro
Phospholipase A
Carboxylic ester hydrolases
Genetic disease
In vivo
Vertebrata
Experimental disease
Mammalia
Biphenyl derivatives
Animal
Hydrolases
Carboxamide
Fluorine Organic compounds
Pharmacokinetics
Antilipemic agent
Online AccessGet full text

Cover

More Information
ISSN:0960-894X
1464-3405
DOI:10.1016/S0960-894X(02)00473-0